Extended Data Fig. 8: Evaluation of T cell activation and anti-tumor efficacy of HER2xCD3xPDL1 and CEAxCD3xPDL1. | Nature Biomedical Engineering

Extended Data Fig. 8: Evaluation of T cell activation and anti-tumor efficacy of HER2xCD3xPDL1 and CEAxCD3xPDL1.

From: A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity

Extended Data Fig. 8: Evaluation of T cell activation and anti-tumor efficacy of HER2xCD3xPDL1 and CEAxCD3xPDL1.

(a) Flow cytometry analysis of CD25, Ki67, TNF-α, and IFN-γ in CD8+ T cells co-cultured with PBMCs and EBC-1 or LS174T cells, treated with HER2xCD3xPDL1 or CEAxCD3xPDL1, respectively. (b) Human PBMCs were reconstituted in NOG mice followed by subcutaneous implantation of EBC-1 or LS174T cells, and treatment with HER2xCD3xPDL1 or CEAxCD3xPDL1. Tumor volume kinetics were measured over time (n=6 mice, mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test).

Source data

Back to article page